ArticleScientific reports2026
Baicalein alleviates Alzheimer's disease pathology in AD models by activating the PI3K/AKT/GSK3β pathway to inhibit neuronal apoptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Baicalein, a bioactive flavonoid from Scutellaria baicalensis, exhibits anti - inflammatory, antioxidant, and neuroprotective properties. Its potential for Alzheimer’s disease (AD) therapy is emerging. This study evaluated its therapeutic efficacy and molecular mechanisms using APP/PS1 transgenic mice and SH - SY5Y - APP/PS1 cells. Morris water maze and novel object recognition tests assessed cognitive deficits in mice. Hippocampal pathology and neuronal apoptosis were examined via Nissl staining, transmission electron microscopy, and TUNEL assay. For SH - SY5Y - APP/PS1 cells, CCK − 8 optimized drug concentrations, while Annexin V - FITC/PI measured apoptosis and ELISA analyzed Aβ1–42. Network pharmacology identified PI3K/AKT as a key target. Baicalein improved cognition, reduced hippocampal neurodegeneration, decreased neuronal apoptosis, and lowered Aβ1–42 accumulation. It activated the PI3K/AKT pathway, increasing p - PI3K/p - AKT/BCL2 and decreasing p - GSK3β/Caspase − 3. These findings demonstrate that baicalein ameliorates AD by inhibiting neuronal apoptosis via the PI3K/AKT/GSK3β cascade, validating its potential as an AD therapeutic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.